TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06773286

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Stimulation
Description: Participants will receive activity-based training (ABT) while receiving concomitant, active spinal stimulation (scTS) applied at the cervical and thoracic spinal segments over the dorsal skin with optimized and customized stimulation parameters. Round self-adhesive electrodes will be placed over the skin at the midline of spinous processes as cathodes and a pair of rectangular anodes electrodes will be placed over the anterior iliac crests of the pelvis. The stimulation waveform is rectangular pulse with 1-ms duration filled with a carrier frequency of 5kHz. Target simulation will be sub-threshold for UE muscle activation and verified by the absence of visible muscle contraction. The stimulation parameters will be adjusted as needed throughout the intervention course based on the participant's performance and comfort level. The intervention will be administered over 2 consecutive weeks, for 30mins/session and 5 sessions/week, as a part of their daily 3-hour therapy.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The sham-control group will go through ABT paired with sham stimulation to control for placebo effects associated with the perception of scTS. Stimulation will be delivered at one cervical location. No stimulation mapping procedure will be performed. During the training session, the stimulation intensity will be briefly ramped up to a level at which the participants report perceiving the stimulation, and then ramped down to 0mA at both the start and the end of session. The stimulator and electrodes will remain attached to the participant while receiving ABT training. The intervention will be administered over 2 consecutive weeks, for 30mins/session and 5 sessions/week, as a part of their daily 3-hour therapy.

Intervention type: OTHER
Group type: OTHER
Intervention: Training only
Description: articipants in ABT group will receive ABT only. ABT will concentrate on activities of gross UE movement, grasping, pinching, gross and fine motor skill. The hand grasp task will focus on grasping objects with different shapes and weights (i.e. weighted container and tennis ball) and placing/removing them from small storage container; the pinch task involves picking up, translating, and releasing small objects with varied sizes (i.e. blocks, dices, marble balls, nuts, etc.). The training therapist selects tasks based on participant's level of impairment and individual goals. The dosage of ABT will be 30 minutes/session, with approximately 15 minutes allocated on each side.
Study: NCT06774209

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: three kinds of examinations
Description: Following the enrollment of patients, both Gallium-68 labeled Fibroblast Activation Protein Inhibitor-04 Positron Emission Tomography/Computed Tomography (68Ga-FAPI-04 PET/CT) and Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) scans are carried out. Additionally, within a one-week interval before and after the aforementioned examinations, Fluorine-18 labeled Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (18F-FDG PET/CT) is performed on the same cohort of patients.
Study: NCT06773754

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Five-days-On and Two-days-Off
Description: Take Fixed-Dose Combination of Bictegravir/Emtricitabine/Tenofovir alafenamide five days a week (Five-days-On and Two-days-Off)
Study: NCT06770556

Intervention type: DEVICE
Group type: OTHER
Intervention: Sham iTBS
Description: Participants will receive sham iTBS

Intervention type: DEVICE
Group type: OTHER
Intervention: Sham iTBS
Description: Participants will receive sham iTBS

Intervention type: DEVICE
Group type: OTHER
Intervention: Sham iTBS
Description: Participants will receive sham iTBS

Intervention type: DEVICE
Group type: OTHER
Intervention: Sham iTBS
Description: Participants will receive sham iTBS

Intervention type: DEVICE
Group type: OTHER
Intervention: Active iTBS
Description: Participants will receive active iTBS

Intervention type: DEVICE
Group type: OTHER
Intervention: Active iTBS
Description: Participants will receive active iTBS

Intervention type: DEVICE
Group type: OTHER
Intervention: Active iTBS
Description: Participants will receive active iTBS

Intervention type: DEVICE
Group type: OTHER
Intervention: Active iTBS
Description: Participants will receive active iTBS

Intervention type: DEVICE
Group type: OTHER
Intervention: 10 Hz TMS
Description: Participant will receive 10 Hz TMS

Intervention type: DEVICE
Group type: OTHER
Intervention: 10 Hz TMS
Description: Participant will receive 10 Hz TMS

Intervention type: DEVICE
Group type: OTHER
Intervention: 1 Hz TMS
Description: Participant will receive 1 Hz TMS

Intervention type: DEVICE
Group type: OTHER
Intervention: 1 Hz TMS
Description: Participant will receive 1 Hz TMS
Study: NCT06181344

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FCR screening and referral program
Description: Five implementation strategies will be conducted individually for each of the study unit at the timepoint when the study unit is being randomly allocated to the implementation condition. For each study unit, all nurses will first receive a half-day training. Each study unit under the implementation condition will receive weekly audit and feedback reports to summarize the proportion of eligible patients, proportion of eligible patients being screened, proportion of patients appropriately referred to JCICC. The senior research assistant with a nursing background will receive training and mentoring from the PI and will be the guided facilitator. The guided facilitator will conduct weekly site visits to address operational issues arise during the implementation. Lastly, while the choice of symptom assessment tool and referral criteria are standardized and cannot be modified, the routine workflow for each study unit can be adjusted according to its context and resources.
Study: NCT05732194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-333
Description: ITI-333 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-333
Description: ITI-333 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-333
Description: ITI-333 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-333
Description: ITI-333 oral solution

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo
Study: NCT04756713

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterine curettage
Description: Manual or electric vacuum aspiration under ultrasound guidance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: conventional chemotherapy will be treated with MTX (1 mg/kg intramuscular) with rescue of FA (15mg orally). In cases of chemoresistance, second-line chemotherapy will be performed with actinomycin-D (Act-D) 1.25 mg intravenous pulse every 14 days. The third line of chemotherapy will be the EMA/CO regimen (, reserving the EP / EMA regimen (E, cisplatin, MTX / Act-D) for the fourth line.
Study: NCT04803760

Intervention type: OTHER
Intervention: A self-administered questionnaire
Description: A self-administered questionnaire will be used to screen Neck disability index, demographic information and ergonomic risk factors.

Intervention type: OTHER
Intervention: A self-administered questionnaire
Description: A self-administered questionnaire will be used to screen Neck disability index, demographic information and ergonomic risk factors.
Study: NCT05732194

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo
Study: NCT06578104

Intervention type: DEVICE
Intervention: PulseSelect™ PFA system
Description: Ablation using the PulseSelect™ PFA system
Study: NCT05655377

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FitMi PD
Description: Exercise using the motion sensing devices and a tablet computer
Study: NCT06498934

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: deep brain stimulation
Description: Stimulation of the dentate nucleus that is paired with upper limb rehabilitation movements.
Study: NCT06771479

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA strain monkeypox attenuated live vaccine (low dose)
Description: Low dose MVA strain monkeypox attenuated live vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA strain monkeypox attenuated live vaccine (low dose)
Description: Low dose MVA strain monkeypox attenuated live vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA strain monkeypox attenuated live vaccine (high dose)
Description: High dose MVA strain monkeypox attenuated live vaccine
Study: NCT06498934

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Rehabilitation movements to improve upper limb function after stroke
Study: NCT06771479

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA strain monkeypox attenuated live vaccine (high dose)
Description: High dose MVA strain monkeypox attenuated live vaccine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vaccine excipient

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vaccine excipient
Study: NCT06770309

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Silkworm pupa powder
Description: Silkworm pupa powder, 2 times a day, two packets (12\*2 g) each time, take with warm water, before meals, for three months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 2 sachets (12\*2 g) twice a day, with warm water, before meals, for three months
Study: NCT06774820

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: self-blocking tenodesis
Description: the LHB tendon is detached from its origin in the superior labrum. This technique supports the self-locking mechanism of the LHB tendon in the bicipital groove by detaching the tendon from the Y-shaped superior glenoid, including the superior labrum. A radiographically visible suture will be attached to the proximal part of the LHB tendon to facilitate later localization of the LHB tendon during imaging (3-0 stainless steel, ethicon).
Study: NCT06498934

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: Rehabilitation movements to improve upper limb function after stroke
Study: NCT06774820

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arthroscopic tenodesis
Description: LHB tendon is detached from its origin, and sutured. Next, the LHB tendon is fixed in the bicipital groove using a 360-lasso loop tenodesis technique. A radiographically visible suture will be attached to the proximal part of the LHB tendon to facilitate subsequent localization of the LHB tendon during imaging (3-0 stainless steel, ethicon).
Study: NCT06771401

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: cervical mucus sampling
Description: Monitoring of menstrual cycle will be conducted in the follicular, ovulatory and luteal phases during which cervical mucus, serum and urine samples will be collected and pelvic ultrasound scans performed (3-5 ultrasound scans/samples within the cycle).
Study: NCT06771167

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Building Community Resilience Program (BCR)
Description: To improve CHW resilience and wellbeing, during each BCR cycle, the 6 participating CBOs will send groups of four to six CHWs to six virtual, hour-long, evidence-based interactive workshops (48-72 CHWs over the 2 cycles).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Building Community Resilience Program (BCR)
Description: To improve CHW resilience and wellbeing, during each BCR cycle, the 6 participating CBOs will send groups of four to six CHWs to six virtual, hour-long, evidence-based interactive workshops (48-72 CHWs over the 2 cycles).
Study: NCT06770972

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Foundations
Description: The FF intervention is 9 sessions, 5 in the prenatal period and 4 in the postpartum period.
Study: NCT05135832

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic patient-reported outcomes regarding symptoms and health-related quality of life
Description: Weekly reporting of patient-reported outcomes for closer contact between patient and clinic between treatment cycles.~The supportive care (including drugs) is similar in the two treatment arms except for the use of electronic patient-reported outcomes.
Study: NCT06232200

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACUPUNCTURE
Description: Acupuncture application will be performed by bilateral needling of The Sanyinjiao (SP6), Yin Ling Quan (SP9), Zu San Li, Leg Three Mile (ST36) , Tai Chong (LIV3), Hegu (LI4), Taixi (KID3) , Zhongliao (BL33) and Guan Yuan (CV4) acupuncture points using sterile, disposable metal acupuncture needles. The needles will remain in place for approximately 20 minutes during the treatment, a total of 8 sessions are planned, 2 per week.
Study: NCT04493892

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Deliver an educational intervention on harmful chemical exposures, such as phthalates, found in hair care products, developed by the research team using empirical evidence with key informant feedback. The intervention will cover phthalates 1) Exposure through HCPs 2) Potential adverse health outcomes for the mother and child 3) Ways to reduce exposure
Study: NCT05783245

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polarcare Machine
Description: Use of Polar Care ice machine as often as possible, but a minimum of three 15 minute uses per day, for the first 3 days after surgery. No single use should last longer than 30 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care ice therapy
Description: Use of commercial reusable ice packs as often as possible, but a minimum of three 15 minute uses per day, for the first 3 days after surgery. No single use should last longer than 30 minutes.
Study: NCT05785819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VLX-1005
Description: VLX-1005, a 12-LOX enzyme inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching VLX-1005
Study: NCT05305807

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postural exercises
Description: Postural correction exercises are effective in improving forward head posture and it effectively decrease neck pain and increase ROM Exercise training and ergonomic guidelines concerning the use of touchscreen smartphones will reduce the risk of developing upper extremity musculoskeletal disorders
Study: NCT06106672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNP-106
Description: CNP-106 is comprised of an antigenic AChR Peptide Pool (\~1 μg of each AChRα and AChRε peptide comprising AChR Peptide Pool Drug Substance per mg particles) dispersed within a negatively charged (-30 to -60 mV) polymer matrix of PLGA (Poly (DL-lactide-co-glycolide, 50:50 acid-end group)) particles (400-800 nm in size).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: CNP-106 Placebo
Study: NCT04634266

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter tricuspid valve treatment (TTVT)
Description: Percutaneous CE-mark approved techniques for transcatheter tricuspid valve treatment (TTVT): These include (I) transcatheter annuloplasty devices (Tricuspid Cardioband) and (II) transcatheter edge-to-edge repair (TriClip, PASCAL).
Study: NCT05344469

Intervention type: OTHER
Intervention: ofatumumab
Description: There is no treatment allocation. Patients administered ofatumumab by prescription that have started as routine medical treatment will be enrolled.

Intervention type: OTHER
Intervention: glatiramer acetate
Description: There is no treatment allocation. Patients administered glatiramer acetate by prescription that have started as routine medical treatment will be enrolled.

Intervention type: OTHER
Intervention: interferon β1
Description: There is no treatment allocation. Patients administered interferon β1 by prescription that have started as routine medical treatment will be enrolled.
Study: NCT06075706

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MC0518
Description: MC0518 will be intravenously infused immediately after thawing.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BAT
Description: BAT including ECP, ATG, etanercept, infliximab or RUX will be administered based on Investigator's decision.
Study: NCT04184635

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VA-ECMO
Description: * The ECMO device will be the CardioHelp (MAQUET, GETINGE, Orléans, France) using the veno-arterial setting and percutaneous femoro-femoral cannulation with MAQUET GETINGE HLS cannulae.~* Intraortic balloon pump will be MEGA 50 cc or 40cc, (MAQUET, GETINGE, Orléans, France).
Study: NCT04959331

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosfomycin Trometamol Salt
Description: Fosfomycin 3 g 2 sachets, taken orally, once daily for two days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrofurantoin
Description: Nitrofurantoin 50 mg pills, taken orally, two pills/8 hours, for five days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pivmecillinam
Description: Pivmecillinam 400 mg pills. taken orally, one pill/8 hours, for three days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosfomycin Trometamol Salt
Description: Fosfomycin 3 g one sachet, taken orally, for one day
Study: NCT04681404

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Knee Arthroplasty
Description: Comparison of TKA, UKA and healthy controls in relation to balance, function and QOL

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Knee Arthroplasty
Description: Comparison of TKA, UKA and healthy controls in relation to balance, function and QOL
Study: NCT05883280

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Binaural beats
Description: The binaural beat audio file consists of pure tones with a frequency of 432 Hz in the left ear and 420 Hz in the right ear. It is played through headphones starting 30 minutes before the end of the surgery.
Study: NCT04316169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: 150 mg b.i.d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: 150 mg b.i.d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: 150 mg b.i.d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: 150 mg b.i.d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 200 mg
Description: Dose level: 200 mg b.i.d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 200 mg
Description: Dose level: 200 mg b.i.d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faslodex
Description: Cohort B will receive Faslodex.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrazole
Description: Cohort A will receive anastrazole or letrozole.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Cohort A will receive anastrazole or letrozole.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 400 mg
Description: Dose level: 400 mg. b.i.d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 400 mg
Description: Dose level: 400 mg. b.i.d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 600 mg
Description: Dose level: 600 mg b.i.d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 600 mg
Description: Dose level: 600 mg b.i.d.
Study: NCT06489717

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SDB assessment
Description: SDB will be assessed by respiratory polygraphy according to clinical standards
Study: NCT06581003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen 99.7 %
Description: The experimental group will undergo HBOT in a specialized chamber at a pressure of 2.0 ATA. Oxygen will be delivered at 100% for 60 minutes.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Oxygen 21 %
Description: The control group will be placed in the same specialized chamber, but pressure will be 1.0 ATA (normobaric), and oxygen will be delivered at 21% (normal oxygen concentration in room air) for 60 minutes.
Study: NCT04995484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belzutifan
Description: Two 40 mg tablets given as a single oral 80 mg dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belzutifan
Description: Two 40 mg tablets given as a single oral 80 mg dose.
Study: NCT05446662

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music therapy
Description: Patients participating in the study will be informed about the application of music therapy in the preoperative period. The patients who will take part in the music group are given 30 minutes the day before the surgery, and 30 minutes a day on the 1st and 2nd days after the surgery. Music that is selected by the researcher and grouped as relaxing music, classical music, sufi music and Turkish folk music will be played. The patients will be listened to the music with headphones that cover the whole ear, and the music will be adjusted to make them feel comfortable.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aromatherapy
Description: Patients participating in the study will be informed about the application of aromatherapy in the preoperative period. During this period, patients undergo elbow test (1 drop of lavender oil will be dripped onto the inside of the patient's elbow, after 20 minutes, it will be evaluated whether an allergic reaction has developed). Lavender oil as aromatic oil will be administered to the patients in the aromatherapy group in the form of inhalation. Lavender oil inhalation (1 drop of 0.1 cc) It will be applied by inhalation with gauze on which 3-4 drops of lavender oil are poured. 30 minutes before surgery. Aromatherapy will be applied four times with an interval of 30 seconds on the 1st and 2nd days before and after the surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Relaxation Exercises
Description: Patients participating in the study will be informed about relaxation exercises in the preoperative period. Progressive relaxation training will be applied to the patients for 30 minutes once a day, on the day before the operation and on the 1st and 2nd days after the operation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand massage
Description: Patients participating in the study will be informed about the application of massage therapy in the preoperative period. 10-15 minutes once in the preoperative period. And in the postoperative period, the 1st and 2nd days are 10-15 minutes. application will be carried out. Lavender oil (Lavandula Angustifolia) will be used in hand massage, sweet almond oil (Prunus Amygladus Sativa) will be used as essential oil.